Manufacturer
Takeda Ireland Limited(IRELAND)
Registraction Number
MAL19056103ACRZ
Content:
Each film-coated tablet contains:
-Ponatinib (as hydrochloride): 45 mg
Indications:
-Chronic Myeloid Leukemia (CML): Used in adult patients with chronic phase, accelerated phase, or blast phase CML who are resistant to dasatinib or nilotinib, intolerant to dasatinib or nilotinib, or have the T315I mutation.
-Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL): Used in adult patients with Ph+ ALL who are resistant to dasatinib, intolerant to dasatinib, or have the T315I mutation2.
Instructions:
Dosage: The recommended starting dose is 45 mg once daily. Treatment should be continued as long as the patient does not show evidence of disease progression or unacceptable toxicity.
Administration: Take the tablet with or without food. Swallow the tablet whole with water. It is important to follow your doctor's instructions regarding the timing and duration of the medication.
Malaysia
